Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.